ArticleClinical rheumatology2009
Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients.
Article in Clinical rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Treatment of Reactive Arthritis with Biological Agents.Current rheumatology reports · 2024Review
- Suppression of IL-12/IL-23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon-γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon-driven diseases.Experimental dermatology · 2022Article
- An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision.Therapeutic advances in musculoskeletal disease · 2020Review
- Targeting inflammatory pathways in axial spondyloarthritis.Arthritis research & therapy · 2019Review
- Biological and genetic evaluation of IL-23/IL-17 pathway in ankylosing spondylitis patients.Central-European journal of immunology · 2019Article
- Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases.Mediators of inflammation · 2019Review
- IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis.Arthritis research & therapy · 2018Observational
- Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.Rheumatology international · 2016Article
- Secukinumab: a promising therapeutic option in spondyloarthritis.Clinical rheumatology · 2016Review
- Extra-Articular Symptoms in Constellation with Selected Serum Cytokines and Disease Activity in Spondyloarthritis.Mediators of inflammation · 2016Article
- Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.Mediators of inflammation · 2015Article
- Cytokine profiles in axial spondyloarthritis.Reumatologia · 2015Article
- Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results.Clinical rheumatology · 2014Article
- Th17 and Th22 cells in psoriatic arthritis and psoriasis.Arthritis research & therapy · 2013Article
- Evaluation of the T helper 17 axis in ankylosing spondylitis.Rheumatology international · 2012Article
- Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response.Arthritis and rheumatism · 2011Article
- Th-17 associated cytokines in patients with reactive arthritis/undifferentiated spondyloarthropathy.Clinical rheumatology · 2011Article
- The potential importance of Toll-like receptors in ankylosing spondylitis.International journal of clinical rheumatology · 2011Article
- Biomarkers in spondyloarthritis.Current rheumatology reports · 2010Review
- IL-23 and IL-17 in ankylosing spondylitis.Rheumatology international · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL-23 is the main inductor in Th17 polarization of naive T cells, inducing IL-17 production. IL-17 has been demonstrated to be elevated in ankylosing spondylitis (AS). The p40 subunit is common to IL-12 and IL-23. We assessed serum and synovial levels of p40 IL12/23 in spondyloarthropathy (SpA) patients and the evolution under anti-TNF. SpA patients fulfilling ESSG criteria were included. Healthy volunteers served as controls. P40 IL12/23 was assessed using Human Quantikine ELISA (R&D Systems), and at the same time, BASDAI, ESR, CRP, IL-17, MMP-3. Patients treated with anti-TNF were evaluated again after 10 weeks of treatment. Statistical analysis used Mann Whitney and correlation tests. Twenty-seven SpA outpatients (20 men), mean age 40.3 years, mean disease duration 10.5 years, HLA B27 positive n = 21, peripheral arthritis n = 8, mean BASDAI 45.7, mean CRP 30.7 mg/l, and 24 controls (12 men), mean age 50.4 years, were included. There is no statistical difference in serum levels of p40IL12/23 between patients (mean 77.8 pg/ml) and controls (103 pg/ml) and between patients with axial and peripheral involvement. Levels were higher in HLA B-27 negative patients (p = 0.02). No statistical correlation was found between p40 IL12/40 serum levels and each of BASDAI, ESR, CRP, serum levels of IL 17, MMP 3. Fourteen AS patients were treated with TNF blockers. Whereas significant reduction in BASDAI, ESR, and CRP were obvious after treatment, there was no significant change in serum level of p40 IL12/23. Mean levels of synovial p40 IL12/23 were higher in SpA patients (n = 6; mean 536 pg/ml) compared to osteoarthritis patients (n = 3; 133 pg/ml) and compared with paired serum SpA levels. These results suggest that serum levels of p40 IL-12/23 may not be considered as a biologic tool of disease activity assessment in SpA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.